



Sheet 1 of 4

USPTO FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Harry R. Davis	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
JK	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
	AE	US2002/0128252	09/12/02	Glombik et al.			
	AF	10/057,534	01/25/02	Harry R. Davis et al.			
	AG	10/057,646	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AN	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
NG	AT	10/166,942	06/11/02	Anima Ghosal et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
JK	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
X	BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
JK	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		

RECEIVED
JAN 13 2003
TECH CENTER 1600 2900



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
CV01382K

SERIAL NO.:
10/057,629

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:
Harry R. Davis

FILING DATE:
January 25, 2002

GROUP:
1614

(Use several sheets if necessary)

18	BV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs)	
	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
1	CF	FR 1103113	10/31/55	FRANCE				X
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)	
	CH	GB 861367	02/22/61	GB	A61K			
	CI	GB 902658	08/09/62	GB	C07D			
	CJ	GB 1415295	11/26/75	GB	C07C	59/26		
	CK	GB 2329334 A	03/24/99	GB	A61K	45/00		
2	CL	JP 028057	10/01/81	JAPAN			X(abs.)	
	CM	JP 121479	12/10/86	JAPAN			X(abs.)	
	CN	JP 136485	05/26/81	JAPAN			X(abs.)	
	CO	JP 180212	03/24/86	JAPAN			X(abs.)	
	CP	JP 219681	04/14/87	JAPAN			X(abs.)	
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
	CS	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)	
	CT	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)	
	CU	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)	
	CV	JP 4356195 A	1993	JAPAN			X(abs.)	
3	CW	JP 4356495	12/10/92	JAPAN			X(abs.)	
4	CX	JP 5058993 A	1993	JAPAN			X(abs.)	
5	CY	JP 61280295 A	1987	JAPAN			X(abs.)	
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
	DD	WO 87/04429	07/30/87	PCT	C07D	205/08		
	DE	WO 88/04656	06/30/88	PCT	C07D	405/04		
	DF	WO 88/05296	07/28/88	PCT	A61K	31/365		
	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
	DH	WO 92/13837	08/20/92	PCT	C07D	205/085		
6	DI	WO 93/02048	02/04/93	PCT	C07D	205/08		
7	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00		
8	DK	WO 93/11150	06/10/93	PCT	C07J	71/00		
9	DL	WO 94/00480	01/06/94	PCT	C07J	71/00		
	DM	WO 94/14433	07/07/94	PCT	A61K	31/395		
	DN	WO 94/17038	08/04/94	PCT	C07D	205/12		
	DO	WO 94/20535	09/15/94	PCT	C07K	13/00		
	DP	WO 95/04533	02/16/95	PCT	A61K	31/445		
	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435		
	DR	WO 95/08532	03/30/95	PCT	C07D	205/08		
10	DS	WO 95/18143	07/6/95	PCT	C07J	71/00		
11	DT	WO 95/26334	10/05/95	PCT	C07D	205/08		

TECH CENTER 1600/2900

JAN 13 2003

RECEIVED

JAN 13 2003
PATENT & TRADEMARK OFFICE

PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:
CV01382K

SERIAL NO.:
10/057,629

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPLICANT:
Harry R. Davis

FILING DATE:
January 25, 2002

GROUP:
1614

(Use several sheets if necessary)

DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
EH	WO 98/01100	01/15/98	PCT	A61K			
EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	


TECH CENTER 1600/2900

JAN 13 2003

RECEIVED

JAN 13 2003
PATENT & TRADEMARK OFFICE

Sheet 4 of 4

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K		SERIAL NO.: 10/057,629	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis		TECH CENTER 1600/2900 JAN 13 2003 RECEIVED	
				FILING DATE: January 25, 2002			
116	FO	WO 00/18395	04/06/00	PCT	A61K	31/215	
	FP	WO 00/20623	04/13/00	PCT	C12P	41/00	
	FQ	WO 00/23415	04/27/00	PCT	C07C	69/734	
	FR	WO 00/23416	04/27/00	PCT	C07C	69/734	
	FS	WO 00/23425	04/27/00	PCT	C07D	209/80	
	FT	WO 00/23445	04/27/00	PCT	C07D	471/12	
	FU	WO 00/23451	04/27/00	PCT	C07D	487/14	
	FV	WO 00/28981	05/25/00	PCT	A61K	31/00	
	FW	WO 00/31548	06/02/00	PCT	G01N	33/68	
	FX	WO 00/32189	06/08/00	PCT	A61K	31/415	
	FY	WO 00/34240	06/15/00	PCT	C07D	205/08	
	FZ	WO 00/37057	06/29/00	PCT	A61K	9/48	
	GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)
	GB	WO 00/38721	07/06/00	PCT	A61K	45/06	
	GC	WO 00/38722	07/06/00	PCT	A61K	45/06	
	GD	WO 00/38723	07/06/00	PCT	A61K	45/06	
117	GE	WO 00/38724	07/06/00	PCT	A61K	45/06	
				DATE CONSIDERED 10/14/02			



Sheet 1 of 4

PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
	APPLICANT: Harry R. Davis	
	FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
18	AA	US2002/0132855	09/19/02	Nelson, et al.			
	AB	US2002/0137689	09/26/02	Glombik et al.			
	AC	US2002/0128253	09/12/02	Glombik et al.			
	AD	US2002/0039774	04/04/02	Kramer et al.			
	AE	US2002/0128252	09/12/02	Glombik et al.			
	AF	10/057,534	01/25/02	Harry R. Davis et al.			
	AG	10/057,646	01/25/02	Harry R. Davis et al.			
	AH	10/057,629	01/25/02	Harry R. Davis			
	AI	10/154,106	05/22/02	Harry R. Davis et al.			
	AJ	10/057,323	01/25/02	Harry R. Davis et al.			
	AK	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AL	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AM	10/247,032	01/25/02	Harry R. Davis			
	AN	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AO	10/247,099	09/19/02	Harry R. Davis et al.			
	AP	10/247,085	09/19/02	John T. Strony			
	AQ	10/247,095	09/19/02	Harry R. Davis			
	AR	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AS	10/247,397	09/19/02	Harry R. Davis et al.			
16	AT	10/166,942	06/11/02	Anima Ghosal et al.			

RECEIVED
JAN 13 2003
TECH CENTER 1600 2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
18	AU	BE 884722 A	12/01/80	BELGIUM	C07D	AG1K	X(abs.)	
	AV	CA 2253769	11/29/99	CANADA	A61K	31/22		
	AW	DE 2046823 A	03/30/72	GERMANY	C07C		X(abs.)	
	AX	DE 2521113 A	03/18/76	GERMANY	C07C	87/34	X(abs.)	
	AY	EP 0002151 A1,B1	05/30/79	EUROPE	C07C	69/67		
	AZ	EP 0010299 B1	02/15/84	EUROPE	A61K	45/06		
	BA	EP 0179559 A2	04/30/86	EUROPE	C07D	405/06		
	BB	EP 0199630 A1	10/29/86	EUROPE	C07D	205/08		
	BC	EP 0199630 B1	09/19/90	EUROPE	C07D	205/08		
	BD	EP 0264231 A1	04/20/88	EUROPE	C07D	205/08		
	BE	EP 0266896 B1	05/11/88	EUROPE	C07D	471/04		
	BF	EP 0274873 B1	07/20/88	EUROPE	C07K	11/00		
18	BG	EP 0288973 B1	11/02/88	EUROPE	C07D	417/06		
	BH	EP 0311366 B1	04/12/89	EUROPE	C07D	471/04		
	BI	EP 0333268 A1	09/20/89	EUROPE	C07F	7/18		
	BJ	EP 0337549 A1	10/18/89	EUROPE	C07D	205/08		
	BK	EP 0337549 B1	10/04/95	EUROPE	C07D	205/08		
	BL	EP 0365364 A2	04/25/90	EUROPE	C07D	205/08		
	BM	EP 0369686 A1	05/23/90	EUROPE	C07D	463/00		
	BN	EP 0375527 A1	06/27/90	EUROPE	C07D	205/08	X(abs.)	
	BO	EP 0401705 A3	12/12/90	EUROPE	A61K	31/66		
	BP	EP 0415487 A2	03/06/91	EUROPE	C07D	205/08		
	BQ	EP 0455042 A1	11/06/91	EUROPE	A61K	31/19		
	BR	EP 0457514 A1	11/21/91	EUROPE	A61K	45/06		
	BS	EP 0457514 B1	08/21/96	EUROPE	A61K	45/06		
	BT	EP 0461548 A3	12/18/91	EUROPE	A61K	31/365		
18	BU	EP 0462667 A2	12/27/91	EUROPE	C07D	205/08		



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. DavisFILING DATE:
January 25, 2002GROUP:
1614

(Use several sheets if necessary)

18	BV	EP 0475148 A1	03/18/92	EUROPE	A61K	31/215		
	BW	EP 0475755 B1	03/18/92	EUROPE	C07D	403/06		
	BX	EP 0481671 A1	04/22/92	EUROPE	C07D	205/08		
	BY	EP 0482498 A3	04/29/92	EUROPE	A61K	31/66		
	BZ	EP 0524595 A1	01/27/93	EUROPE	C07D	205/08		
	CA	EP 0720599 B1	07/10/96	EUROPE	C07D	205/08		
	CB	EP 0793958 A2	09/10/97	EUROPE	A61K	9/16	X(abs)	
	CC	EP 0814080 A1	12/29/97	EUROPE	C07D	267/14		
	CD	EP 0904781 A2	03/31/99	EUROPE	A61K	31/215		
	CE	EP 1048295 A2	11/02/00	EUROPE	A61K	31/216		
T	CF	FR 1103113	10/31/55	FRANCE				X
	CG	FR 2779347	12/10/97	FRANCE	A61	031/215	X(abs.)	
	CH	GB 861367	02/22/61	GB	A61K			
	CI	GB 902658	08/09/62	GB	C07D			
	CJ	GB 1415295	11/26/75	GB	C07C	59/26		
	CK	GB 2329334 A	03/24/99	GB	A61K	45/00		
2	CL	JP 028057	10/01/81	JAPAN			X(abs.)	
	CM	JP 121479	12/10/86	JAPAN			X(abs.)	
	CN	JP 136485	05/26/81	JAPAN			X(abs.)	
	CO	JP 180212	03/24/86	JAPAN			X(abs.)	
	CP	JP 219681	04/14/87	JAPAN			X(abs.)	
	CQ	JP 5194209 A	08/03/93	JAPAN	A61K	031/22	X(abs.)	
	CR	JP 5239020 A	1993	JAPAN	C07D	205/08	X(abs.)	
	CS	JP 4054182 A	1992	JAPAN	C12P	017/16	X(abs.)	
	CT	JP 63017859 A	1988	JAPAN	C07D	205/08	X(abs.)	
	CU	JP 4266869 A	1992	JAPAN	C07D	205/08	X(abs.)	
	CV	JP 4356195 A	1993	JAPAN			X(abs.)	
4	CW	JP 4356495	12/10/92	JAPAN			X(abs.)	
6	CX	JP 5058993 A	1993	JAPAN			X(abs.)	
8	CY	JP 61280295 A	1987	JAPAN			X(abs.)	
	CZ	JP 95051558 B2	06/05/95	JAPAN	C07D	205/08	X(abs.)	
	DA	JP 91068020	10/25/91	JAPAN	C07D	205/08	X(abs.)	
	DB	JP 94047573	06/22/94	JAPAN	C07D	205/08	X(abs.)	
	DC	WO 82/01649	05/27/82	PCT	A61K	9/52	X(abs.)	
	DD	WO 87/04429	07/30/87	PCT	C07D	205/08		
	DE	WO 88/04656	06/30/88	PCT	C07D	405/04		
	DF	WO 88/05296	07/28/88	PCT	A61K	31/365		
	DG	WO 91/03249	03/21/91	PCT	A61K	31/785	X(abs.)	
	DH	WO 92/13837	08/20/92	PCT	C07D	205/085		
9	DI	WO 93/02048	02/04/93	PCT	C07D	205/08		
1	DJ	WO 93/07167	04/15/93	PCT	C07J	71/00		
3	DK	WO 93/11150	06/10/93	PCT	C07J	71/00		
5	DL	WO 94/00480	01/06/94	PCT	C07J	71/00		
	DM	WO 94/14433	07/07/94	PCT	A61K	31/395		
	DN	WO 94/17038	08/04/94	PCT	C07D	205/12		
	DO	WO 94/20535	09/15/94	PCT	C07K	13/00		
	DP	WO 95/04533	02/16/95	PCT	A61K	31/445		
	DQ	WO 95/06470	03/09/95	PCT	A61K	31/435		
	DR	WO 95/08532	03/30/95	PCT	C07D	205/08		
7	DS	WO 95/18143	07/6/95	PCT	C07J	71/00		
10	DT	WO 95/26334	10/05/95	PCT	C07D	205/08		

TECH CENTER 1000/2900

JAN 13 2003

RECEIVED



PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629APPLICANT:
Harry R. DavisFILING DATE:
January 25, 2002GROUP:
1614

DU	WO 95/28919	11/02/95	PCT	A61K	31/19	X(abs.)	
DV	WO 96/00288	01/04/96	PCT	C12N	15/12		
DW	WO 96/09827	04/04/96	PCT	A61K	31/58		
DX	WO 96/16037	05/30/96	PCT	C07D	205/08		
DY	WO 96/19987	07/04/96	PCT	A61K	31/35		
DZ	WO 96/40255	12/19/96	PCT	A61K	45/06		
EA	WO 97/16455	05/09/97	PCT	C07H	3/04		
EB	WO 97/18304	05/22/97	PCT	C12N	15/00		
EC	WO 97/25042	07/17/97	PCT	A61K	31/42		
ED	WO 97/28149	08/07/97	PCT	C07D	307/79		
EE	WO 97/31907	09/04/97	PCT	C07D	263/56		
EF	WO 97/35576	10/02/97	PCT	A61K	31/44		
EG	WO 97/46238	12/11/97	PCT	A61K	31/245		
EH	WO 98/01100	01/15/98	PCT	A61K			
EI	WO 98/05331	02/12/98	PCT	A61K	31/45		
EJ	WO 98/14179	04/09/98	PCT	A61K	9/50		
EK	WO 98/31360	07/23/98	PCT	A61K	31/19		
EL	WO 98/31361	07/23/98	PCT	A61K	31/215	X(abs.)	
EM	WO 98/31366	07/23/98	PCT	A61K	31/445		
EN	WO 98/43081	10/01/98	PCT	G01N	33/50		
EO	WO 98/46215	10/22/98	PCT	A61K	9/20		
EP	WO 98/47518	10/29/98	PCT	A61K	31/715		
EQ	WO 98/57652	12/23/98	PCT	A61K	31/785		
ER	WO 99/04815	04/02/99	PCT	A61K	45/00	X(abs.)	
ES	WO 99/06035	02/11/99	PCT	A61K	31/00		
ET	WO 99/06046	02/11/99	PCT	A61K	31/455		
EU	WO 99/09967	03/04/99	PCT	A61K	31/00		
EV	WO 99/12534	03/18/99	PCT	A61K	31/17	X(abs.)	
EW	WO 99/11260	03/11/99	PCT	A61K	31/40		
EX	WO 99/15159	04/01/99	PCT	A61K	31/00		
EY	WO 99/15520	04/01/99	PCT	C07D	319/20	X(abs.)	
EZ	WO 99/18072	04/15/99	PCT	C07D	205/08		
FA	WO 99/20275	04/29/99	PCT	A61K	31/47		
FB	WO 99/20614	04/29/99	PCT	C07D	265/36		
FC	WO 99/29300	06/17/99	PCT	A61K	9/107		
FD	WO 99/38498	08/05/99	PCT	A61K	31/00		
FE	WO 99/38845	08/05/99	PCT	C07D	213/65		
FF	WO 99/38850	08/05/99	PCT	C07D	237/32		
FG	WO 99/46232	09/16/99	PCT	C07C	62/34	X(abs.)	
FH	WO 99/47123	09/23/99	PCT	A61K	9/16		
FI	WO 99/48488	09/30/99	PCT	A61K	31/00		
FJ	WO 99/66929	12/29/99	PCT	A61K	31/405		
FK	WO 99/66930	12/29/99	PCT	A61K	31/405		
FL	WO 00/04011	01/27/00	PCT	C07D	319/06		
FM	WO 00/07617	02/17/00	PCT	A61K	38/26		
FN	WO 00/16749	03/30/00	PCT	A61K	9/16	X(abs.)	

RECEIVED
JAN 13 2003
TECH CENTER 1600/2900



PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. DavisFILING DATE:
January 25, 2002GROUP:
1614

(Use several sheets if necessary)

W6	FO	WO 00/18395	04/06/00	PCT	A61K	31/215		
	FP	WO 00/20623	04/13/00	PCT	C12P	41/00		
	FQ	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FR	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FS	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FT	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FU	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FV	WO 00/28981	05/25/00	PCT	A61K	31/00		
	FW	WO 00/31548	06/02/00	PCT	G01N	33/68		
	FX	WO 00/32189	06/08/00	PCT	A61K	31/415		
	FY	WO 00/34240	06/15/00	PCT	C07D	205/08		
	FZ	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GA	WO 00/37078	06/29/00	PCT	A61K	31/44	X(abs.)	
	GB	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GC	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GD	WO 00/38723	07/06/00	PCT	A61K	45/06		
W6	GE	WO 00/38724	07/06/00	PCT	A61K	45/06		

DATE CONSIDERED

10/14/02

TECH CENTER 1600/2900

JAN 13 2003

RECEIVED

APR 14 2003

Sheet 1 of 9

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: Harry R. Davis	
		FILING DATE: January 25, 2002	GROUP: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	FQ	US2003/0013729	01/16/03	Iqbal, et al.	514	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	FR	WO 96/19450	06/27/96	PCT	C07D	205/08		
	FS	WO 97/21676	06/19/97	PCT	C07D	205/09		
	FT	WO 97/41098	11/06/97	PCT	C07D	205/09		
	FU	WO 00/23415	04/27/00	PCT	C07C	69/734		
	FV	WO 00/23416	04/27/00	PCT	C07C	69/734		
	FW	WO 00/23425	04/27/00	PCT	C07D	209/80		
	FX	WO 00/23445	04/27/00	PCT	C07D	471/12		
	FY	WO 00/23451	04/27/00	PCT	C07D	487/14		
	FZ	WO 00/28981	05/25/00	PCT	A61K	31/00		
	GA	WO 00/31548	06/02/00	PCT	G01N	33/68		
	GB	WO 00/32189	06/08/00	PCT	A61K	31/415		
	GC	WO 00/34240	06/15/00	PCT	C07D	205/08		
	GD	WO 00/37057	06/29/00	PCT	A61K	9/48		
	GE	WO 00/37078	06/29/00	PCT <i>abstract only</i>	A61K	31/44	X(abs.)	
	GF	WO 00/38721	07/06/00	PCT	A61K	45/06		
	GG	WO 00/38722	07/06/00	PCT	A61K	45/06		
	GH	WO 00/38723	07/06/00	PCT	A61K	45/06		
	GI	WO 00/38724	07/06/00	PCT	A61K	45/06		
	GJ	WO 00/38725	07/06/00	PCT	A61K	45/06		
	GK	WO 00/38726	07/06/00	PCT	A61K	45/06		
	GL	WO 00/38727	07/06/00	PCT	A61K	45/06		
	GM	WO 00/38728	07/06/00	PCT	A61K	45/06		
	GN	WO 00/38729	07/06/00	PCT	A61K	45/06		
	GO	WO 00/40247	07/13/00	PCT	C07D	265/26		
	GP	WO 00/45817	08/10/00	PCT	A61K	31/505		
	GQ	WO 00/50392	08/31/00	PCT <i>abstract only</i>	C07C	323/52	X(abs.)	
	GR	WO 00/53149	09/14/00	PCT	A61K			
	GS	WO 00/53173	09/14/00	PCT	A61K	31/22		
	GT	WO 00/53563	09/14/00	PCT <i>abstract only</i>	C07C	59/92	X(abs.)	
	GU	WO 00/56403	09/28/00	PCT	A61P	9/10		
	GV	WO 00/57859	10/05/00	PCT	A61K	9/48		
	GW	WO 00/57918	10/05/00	PCT	A61K	47/44		
	GX	WO 00/60107	10/12/00	PCT	C12P	17/10		
	GY	WO 00/63153	10/26/00	PCT	C07C	69/734		
	GZ	WO 00/63161	10/26/00	PCT	C07C	237/30		
	HA	WO 00/63190	10/26/00	PCT	C07D	265/38		
	HB	WO 00/63196	10/26/00	PCT	C07D	277/04		
	HC	WO 00/63209	10/26/00	PCT	C07D	471/04		
	HD	WO 00/63703	10/26/00	PCT	C07D	33/92		

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

APR 14 2003

Sheet 2 of 9

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. DavisFILING DATE:
January 25, 2002GROUP:
1614

(Use several sheets if necessary)

MS	HE	WO 00/69412	11/23/00	PCT	A61K	9/127		
	HF	WO 00/69445	11/23/00	PCT	A61K	31/785		
	HG	WO 00/72825	12/7/00	PCT	A61K	9/14		
	HH	WO 00/72829	12/07/00	PCT	A61K	9/48		
	HI	WO 00/75103	12/14/00	PCT abstract only	C07C	235/60	X(abs.)	
	HJ	WO 00/76482	12/21/00	PCT	A61K	9/48		
	HK	WO 00/76488	12/21/00	PCT	A61K	31/00		
	HL	WO 00/78312	12/28/00	PCT	A61K	31/421		
	HM	WO 00/78313	12/28/00	PCT	A61K	31/422		
	HN	WO 01/00579	01/04/01	PCT	C07D	213/65		
	HO	WO 01/00603	01/04/01	PCT	C07D	277/24		
	HP	WO 01/08686	02/08/01	PCT	A61K	31/495		
	HQ	WO 01/12176	02/22/01	PCT	A61K	31/16		
	HR	WO 01/12187	02/22/01	PCT	A61K	31/404		
	HS	WO 01/12612	02/22/01	PCT	C07D	257/04		
	HT	WO 01/14349	03/01/01	PCT abstract	C07D	277/34	X(abs.)	
	HU	WO 01/14350	03/01/01	PCT	C07D	277/34	X(abs.)	
	HV	WO 01/14351	03/01/01	PCT abstract	C07D	277/34	X(abs.)	
	HW	WO 01/15744	03/08/01	PCT	A61K	49/00		
	HX	WO 01/16120	03/08/01	PCT	C07D	263/32		
	HY	WO 01/17994	03/15/01	PCT	C07D	413/12		
	HZ	WO 01/18210	03/15/01	PCT	C12N	15/12		
	IA	WO 01/21181	03/29/01	PCT abstract	A61K	31/675	X(abs.)	
	IB	WO 01/21259	03/29/01	PCT	A61P			
	IC	WO 01/21578	03/29/01	PCT abstract	C07C	235/60	X(abs.)	
	ID	WO 01/21647	03/29/01	PCT	C07K	14/00		
	IE	WO 01/22962	04/05/01	PCT	A61K	31/435		
	IF	WO 01/25225	04/12/01	PCT	C07D	317/18		
	IG	WO 01/25226	04/12/01	PCT	C07D	327/04		
	IH	WO 01/30343	05/03/01	PCT	A61K	31/40		
	II	WO 01/32161	05/10/01	PCT	A61K	31/00		
	IJ	WO 01/35970	05/25/01	PCT	A61K	35/76		
	IK	WO 01/40192	06/07/01	PCT abstract	C07D	217/26	X(abs.)	
	IL	WO 01/45676	06/28/01	PCT	A61K	9/24		
	IM	WO 01/49267	07/12/01	PCT	A61K	9/14		
	IN	WO 01/64221	09/07/01	PCT	A61K	31/52		
	IO	WO 01/76632	10/18/01	PCT	A61K	45/06		
	IP	WO 02/50090	06/27/02	PCT	C07H	15/26		
	IQ	WO 02/058696	08/01/02	PCT	A61K	31/397		
	IR	WO 02/058731	08/01/02	PCT	A61K	45/06		
	IS	WO 02/058732	08/01/02	PCT	A61K	45/06		
	IT	WO 02/058733	08/01/02	PCT	A61K	45/06		
	IU	WO 02/058734	08/01/02	PCT	A61K	45/06		
	IV	WO 02/058685	08/01/02	PCT	A61K	31/00		
	IW	WO 02/064130	08/22/02	PCT	A61K	31/195		
	IX	WO 02/064549	08/22/02	PCT	C07C	275/34		
W	IY	WO 02/064664	08/22/02	PCT	C08G	77/02		

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

APR 14 2003

Sheet 3 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K		SERIAL NO.: 10/057,629	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis			
				FILING DATE: January 25, 2002		GROUP: 1614	
IZ	WO 02/072104	09/19/02	PCT	A61K	31/54		
JA	WO 02/081454	10/17/02	PCT	C07D	239/36		
JB	WO 02/26729	04/04/02	PCT	C07D	311/66		
JC	WO 02/064094	08/22/02	PCT	A61K			
JD	WO 03/018024	03/06/03	PCT	A61K	31/55		
JE	WO 03/018059	03/06/03	PCT	A61K	45/06		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
JF	Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" <i>Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.</i> , 8:313-318 (1998)						
JG	Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", <i>Bioganic & Medicinal Chem. Ltrs. Oxford, G.B.</i> 8:319-322 (1998)						
JH	H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E Knockout Mice", <i>Arterioscler, Thromb. Vasc. Biol</i> 21:2032-2038, (Dec. 2001)						
JI	Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", <i>Chemical Abstracts No. 15</i> , 86 (April 11, 1997)						
JJ	Otto et al., "Stereochemistry of dehydration and halogenation of αR^* and αS^* isomeric 3-(α -hydroxybenzyl)-1,4 diphenyl-2 azetidinones", <i>Chemical Abstracts No. 19</i> , 99 (Nov. 7, 1983)						
JK	T. Durst et al., "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" <i>Canadian Journal of Chemistry</i> , 50:3196-3201 (1971)						
JL	Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" <i>Chemical Abstracts No. 106</i> , 17 (April 27, 1987)						
JM	M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", <i>J. Agric. Food Chem.</i> , 30:920-924 (1982)						
JN	H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", <i>Liebigs Ann. Chem.</i> 1152-1161 (1983)						
JO	G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" <i>Tetrahedron Letters</i> , 26:3903-3906 (1985)						
JP	Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", 26 <i>Tetrahedron Letters</i> , 45:5493-5496 (1985)						
JQ	Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" 24 <i>Heterocycles</i> 6:1609-1617 (1986)						
JR	D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" <i>Drugs</i> 36:63:71 (1988)						
JS	Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" <i>Circulation</i> 80:1101-1114 (1989)						
JT	B. Ram et al. "Potential Hypolipidemic agents: Part V", 29B <i>Indian J. Chem.</i> 1134-37 (1990)						
JU	Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA: Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" <i>Comp. Biochem. Physiol.</i> 99A:665-670 (1991)						
JV	Horie, M. et al, "Hypolipidemic effects of NB-598 in dogs" <i>Atherosclerosis</i> 88:183-192 (1991)						
JW	Baxter, A., "Squalestatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", <i>The Journal of Biological Chemistry</i> 267:11705-11708 (1992)						
JX	Summary Factfile, "Anti-Atherosclerotic Agents" <i>Current Drugs Ltd.</i> (1992)						

RECEIVED

APR 15 2003

TECH CENTER 1600/2000

APR 14 2003

Sheet 4 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	GROUP: 1614
JY	18	Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" <i>Journal of Lipid Research</i> 34:377-395 (1993)			
JZ		Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" <i>Atherosclerosis</i> 115:45-63 (1995)			
KA		Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Viro Activity" <i>Journal of Medicinal Chemistry</i> 38:1600-1607 (1995)			
KB		Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" <i>Atherosclerosis</i> pp. 311-315 (1995)			
KC		Vaccaro, W. et al., "2-Azetidinone Cholesterol Absorption Inhibitors; Increased Potency by Substitution of the C-4 Phenyl Ring", <i>Bioorg. & Med. Chem.</i> 6:1429-1437 (1998)			
KD		G. Wu et al, "A Novel One-Step Diastereo- and enantioselective formation of trans-azetidinones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (4/21/99).			
KE		B. Staels, "New Roles for PPARS in Cholesterol Homeostasis", <i>Trends in Pharmacological Sciences</i> , 22:9 p. 444 (Sept. 2001)			
KF		Abbott et al, "Tricor® Capsules, Micronized", <i>Physicians Desk Reference</i> , January 8, 2001.			
KG		M. Feher et al., 1991, <i>Lipids and Lipid Disorders</i> , p.1-87 (1991).			
KH		M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", <i>Trends in Pharmacological Science</i> , Vol. 22, No. 9 441-443 (2001)			
KI		C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", <i>J. Clin. Pharm.</i> 41:1 70-78 (Jan. 2001)			
KJ		W. Oppolzer et al., "Asymmetric Diels - Alder Reactions, Facile Preparation and Structure of Sulfonamido - Isobornyl Acrylates", <i>Tetrahedron Letters</i> No. 51, 25:5885-5888 (1984).			
KK		M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", <i>Expert Opinion Investigating Drugs</i> , 11:2663-71, (Nov. 2000)			
KL		M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", <i>159 Arch. Intern. Med.</i> 16 1893-900 (Sept. 1999)			
KM		I. Wester, "Cholesterol - Lowering effect of plant sterols", <i>Euro. J.Lipid, Sci. Tech.</i> 37-44 (2000).			
KN		A. Andersson et al., "Cholesterol -lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", <i>1 European Heart. J. Supplements</i> S80 - S90 (1999)			
KO		H. Gylling et al, "Reduction of Serum Cholesterol in Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine", <i>96 Circulation</i> 12 4226-4231 (Dec. 16, 1997)			
KP		T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", <i>New England Journal of Med.</i> 333 1308-1312 (Nov. 16, 1995)			
KQ		T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", <i>Arterioscler Thromb Vasc. Biol.</i> 70-79 (Jan. 2000)			
KR	18	M. Van Heek et al., "In Vivo Metabolism - Based Discovery of a Novel Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," <i>283 J. Pharmaceutical and Experimental Therapeutics</i> 1 157-163 (1997)			

RECEIVED

APR 15 2003

TECH CENTER 1600/2000

APR 14 2003

Sheet 5 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	GROUP: 1614
MS	KS	H. Davis <i>et al.</i> , "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," 151 <i>Atherosclerosis</i> 1:133 (July 2000)			
	KT	L. Nguyen <i>et al.</i> , "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", 10 <i>Atherosclerosis</i> 2, 289-297 (1990)			
	KU	L. Nguyen <i>et al.</i> , "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and dietary sterol restriction," 32 <i>J. Lipid Res.</i> 1941-1948 (1991)			
	KV	M. Cobb <i>et al.</i> , "Sitosterolemia: Opposing Effects of cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," 45 <i>Metabolism</i> 6 673-679 (June 1996)			
	KW	M. Huettinger <i>et al.</i> , "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", 13 <i>Arteriosclerosis and Thrombosis</i> 7 1005-1012 (July 1993).			
	KX	J. Best <i>et al.</i> , "Diabetic Dyslipidaemia", 59 <i>Drugs</i> 5 1101-1111 (May 2000)			
	KY	P. Chong, <i>et al.</i> , "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", 60 <i>Drugs</i> 1 55-93 (July 2000)			
	KZ	M. Brown <i>et al.</i> , "A Receptor - Mediated Pathway for Cholesterol Homeostasis", 232 <i>Science</i> 34-47 (April 4, 1986)			
	LA	L. Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", <i>JACC</i> 257A (Feb. 2000)			
	LB	Medical Economics, Co., Inc., <i>Physician's Desk Reference</i> , 207-208, 2054 (55 th Ed. 2001)			
	LC	K. Fassbender <i>et al.</i> , "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides $A\beta$ 42 and $A\beta$ 40 in vitro and in vivo", <i>PNAs Early Edition</i> , www.phas.org/cgi/doi/10.1073/phas.081620098 (2001)			
	LD	Andrx Announces Results of Alzheimer's Disease Clinical Study", <i>Andrx Corporate Release</i> (April 11, 2001)			
	LE	Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130", <i>US Bancorp Piper</i> , April 12, 2001			
	LF	Statins May Protect Against Alzheimer's Disease; much research needed", <i>Geriatrics</i> February 2001			
	LG	Dementia and Statins", <i>The Lancet</i> March 17, 2001			
	LH	Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers", <i>Reuters</i> April 11, 2001			
	LI	Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com April 10, 2001			
	LJ	Lovastatin XL of Use in Alzheimer's? <i>News Edge</i> (May 2, 2001)			
	LK	L. Refolo <i>et al.</i> , "Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, <i>Neurobiology of Disease</i> 321-331 (2000)			
	LL	D. Kang <i>et al.</i> , "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor - Related Protein Pathway", <i>Journal of Clinical Investigation</i> 106:9, 1159-1166 (Nov. 2000)			
	LM	Y.A. Kesaniewmi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", <i>J. Clin. Invest.</i> 80(2) 578-81 (Aug. 1987)			
	LN	J. Busciglio <i>et al.</i> , "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", 90 <i>Proc. Natl. Acad. Sci. USA</i> , 2092-2096 <i>Neurobiology</i> (March 1993)			
	LO	L. Farrer <i>et al.</i> , "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", <i>Annals of Neurology</i> 25:5, 485-493 (May 1989)			
MS	LP	A. Goate <i>et al.</i> , "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", 349 <i>Nature</i> No. 631 704-706 (Feb. 21, 1991)			

RECEIVED

APR 16 2003

TECH CENTER 1Ann/2000

APR 14 2003

Sheet 6 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
		GROUP: 1614			
118	LQ	D. Mann <i>et al.</i> , "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", 89 <i>J. Neuro. Sci.</i> , 169-179 (Feb. 1989)			
	LR	G. McKhann <i>et al.</i> , "Clinical Diagnosis of Alzheimer's Disease", 34 <i>Neurology</i> No. 7, 939-944 (July 1984)			
	LS	D. Selokoe, "Alzheimer's Disease: Genotypes, Pheontype and Treatments", 275 <i>Science</i> , 630-631 (Jan. 31, 1997)			
	LT	C. Van Duijn, <i>et al.</i> , "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", 20 <i>Int'l J. Epidemiology</i> No. 2 (Suppl. 2), 513-520 (1991)			
	LU	T Nagahara <i>et al.</i> , "Dibasic (Amidcinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", <i>J. Med. Chem</i> 37:1200-1207 (1994)			
	LV	Mellott <i>et al.</i> , "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistatin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", <i>Circulation Research</i> , 70:1152-1160 (1992)			
	LW	Sitko <i>et al.</i> , "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", <i>Circulation</i> , 85:805-815 (1992)			
	LX	Seymour <i>et al.</i> , 1994, <i>Biochemistry</i> , 33:3949-3959			
	LY	Markwardt, 1994, <i>Thrombosis and Hemostasis</i> , 72:477-479			
	LZ	Mendall <i>et al.</i> , "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", <i>BMJ</i> , 312:1061-1065 (April 27, 1996)			
	MA	Ridker P. <i>et al.</i> , "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", 46 <i>J. Investig. Med.</i> , 8:391-395 (1998)			
	MB	L. Gruberb, 2000, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive protein (CRP) and Chlamydia", <i>American Heart Association Scientific Sessions</i>			
	MC	Waters, D. <i>et al.</i> , "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", <i>Circulation</i> , 82:1940-1953 (1990)			
	MD	Fleckenstein, 1985, <i>Cir. Res.</i> Vol 52 (Suppl. 1) 3-16			
	ME	Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", <i>John Wiley, New York</i> , pp. 286-313			
	MF	McCall, D., 1985, "Curr. Pract. Cardiol. Vol. 10, 1-11			
	MG	Remington 1995, "The Science and Practice of Pharmacy, (19 th Ed. 1995) p. 963			
	MH	M. Chistie <i>et al.</i> , "Early - Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", 276 <i>J. Biol. Chem.</i> No. 24; 21562-70 (June 15, 2001)			
	MI	C. Janus <i>et al.</i> , "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", 408 <i>Nature</i> 21/28; 979-982 (Dec. 2000)			
	MJ	Manual of Laboratory Operations, "Lipid Research Clinics Program Report, Washington, D.C., U.S. Dept. of Health, Education and Welfare Publication; 1:75-628 (1974)			
	MK	Steiner, PM <i>et al.</i> , "Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], <i>J. Clin. Chem. Clin. Bichem</i> , 19:850 (1981)			
	ML	Steele WG, <i>et al.</i> , "Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, 22 <i>Clin. Chem.</i> , 1:98-101 (1976)			
118	MM	Salen <i>et al.</i> , "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", <i>J. Lipid Res.</i> , 30:1319-1330 (1989)			

RECEIVED

APR 15 2003

TECH CENTER 1000/2500

APR 14 2003

Sheet 7 of

RECEIVED
APR 15 2003
TECH CENTER 1800 2300

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	GROUP: 1614
MS	MN	Lutjohann <i>et al.</i> , "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", <i>J. Lipid Res.</i> , 36 :8; 1763-1773 (1995)			
	MO	Zhang <i>et al.</i> , "Calpain Inhibitor I Increases B- Amyloid Peptide by Inhibiting the Degradation of the Substrate of γ - Secretase" 274 J. Biol. Chem. , 13:8966-8972 (1999)			
	MP	Zhang <i>et al.</i> , "Biochemical Characterization of the γ -Secretase Activity that Produces B-Amyloid Peptides", <i>Biochemistry</i> 40 :5049-5055 (2001)			
	MQ	Ida <i>et al.</i> , "Analysis of Heterogeneous BA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay", 271 J. Biol. Chem. ; 37:22908-22914 (1996)			
	MR	Lichtlen, P.R. <i>et al.</i> , 1990, <i>Lancet</i> , 335 :1109-1113			
	MS	Bays <i>et al.</i> , "Effectiveness and Tolerability of Ezetimibe in Patients with Primary Hypercholesterolemia: Pooled Analysis of Two Phase II Studies", <i>Clinical Therapeutics</i> , 23 :1209-1230 (2001)			
	MT	E. Leitersdorf <i>et al.</i> , "Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management", <i>European Heart Journal Supplement</i> , 3 :E17-E23 (June 2001)			
	MU	Bauer <i>et al.</i> , "Ezetimibe Does not Affect the Pharmacokinetics or Pharmacodynamics of Warfarin", <i>Clinical Pharmacology and Therapeutics</i> , 69 :2 p5 (Mar. 6-10, 2001)			
	MV	Keung <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics of oral Contraceptives", <i>Clinical Pharmacology and Therapeutics</i> , 69 :2 p55 (Mar. 6-10, 2001)			
	MW	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs 72nd EAS Congress</i> , p. 38 (May 21-23, 2001)			
	MX	T. Kosoglou <i>et al.</i> , "Coadministration of Ezetimibe and Fenofibrate Leads to Favorable Effects On Apo CII and LDL Subfractions", <i>Posters 11. Lipid Lowering Drugs/Novel, 72nd EAS Congress</i> , p. 89 (May 21-23, 2001)			
	MY	L. Reyderman <i>et al.</i> , "Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Gemfibrozil", Presented at XIV Int'l Symp. on Drugs Affecting Lipid Metabolism (DALM) N.Y. (Sept. 9-12, 2001)			
	MZ	P. Statkevich <i>et al.</i> , "Ezetimibe Does Not Affect the Pharmacokinetics and Pharmacodynamics of Glipizide", <i>Clinical Pharmacology & Therapeutics</i> , 69 :67 (March 6-10, 2001)			
	NA	Knopp <i>et al.</i> , "Effect of Ezetimibe on Serum Concentrations of Lipid-Soluble Vitamins", <i>Posters 11. Lipid Lowering Drug/Novel 72nd EAS Congress</i> , p. 90 (May 21-23, 2001)			
	NB	Kosoglou <i>et al.</i> , "Pharmacodynamic Interaction Between Fenofibrate and the Cholesterol Absorption Inhibitor Ezetimibe", <i>Workshops Lipid Lowering Drugs, 72nd EAS Congress</i> , p. 38 (March 6-10, 2001)			
NC	Bays <i>et al.</i> , "Low-Density Lipoprotein Cholesterol Reduction By SCH 58235 (Ezetimibe), A Novel Inhibitor of Intestinal Cholesterol Absorption, in 243 Hypercholesterolemic Subjects: Results of a Dose-Response Study", <i>XII International Symposium on Atherosclerosis, Stockholm, Sweden (June 25-29, 2000)</i>				
ND	Castaner <i>et al.</i> , "Ezetimibe - Hypolipidemic Cholesterol Absorption Inhibitor", <i>Drugs of the Future</i> , 25 (7):679-685 (2000)				
NE	Lipka <i>et al.</i> , "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by Ezetimibe (SCH 58235): Pooled Analysis of Two Phase II Studies", <i>American College of Cardiology Annual Meeting, Anaheim, CA (March 12-15, 2000)</i>				
NF	Van Heek <i>et al.</i> , "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor . SCH58235, and its glucuronide, SCH60663", <i>British Journal of Pharmacology</i> , 129 :1748-1754 (2000)				

APR 14 2003


Sheet 8

RECEIVED
TECH CENTER 1600/2300
APR 15 2003

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,822
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
				GROUP: 1614	
NG	MD	Van Heek <i>et al.</i> , 2000, "The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically", <i>XII International Symposium of Atherosclerosis, Stockholm Sweden (June 25-29, 2000)</i>			
NH		Iannucci <i>et al.</i> , "Metabolism of SCH 58235 in the Human, Rat and Dog", <i>47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX (June 13-17, 1999)</i>			
NI		Reiss <i>et al.</i> , "An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors", <i>Bioorganic & Medicinal Chemistry</i> , 7:2199-2202 (1999)			
NJ		Rosenblum <i>et al.</i> , "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption", <i>J. Med. Chem.</i> 41:973-980 (1998)			
NK		Vaccaro <i>et al.</i> , "Sugar-Substituted 2-Azetidinone Cholesterol Absorption Inhibitors: Enhanced Potency by Modification of the Sugar", <i>Bioorganic & Medicinal Chemistry Letters</i> , 8:313-318 (1998)			
NL		Zaks <i>et al.</i> , "Enzymatic Glucuronidation of a Novel Cholesterol Absorption Inhibitor, SCH 58235", <i>Applied Biochemistry and Biotechnology</i> , 73:205-214 (1998)			
NM		W. Insull <i>et al.</i> , "Postmenopausal Hypercholesterolemic Women Derive Additive Benefit from Raloxifene and Simvastatin on Lipid Parameters", <i>World Heart Federation 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke - Abstract Book</i> , p. 35 (June 12-15, 2002)			
NN		L. Simons <i>et al.</i> , 2002, "Ezetimibe added to on-going statin therapy for treatment of primary hypercholesterolemia: Efficacy and safety in patients with Type 2 diabetes mellitus", presented at the 38 th Annual Meeting of the EASD, September 1-5, 2002			
NO		C. Allain <i>et al.</i> , 1974, "Enzymatic Determination of Total Serum Cholesterol", <i>Clinical Chemical</i> , 20:470-475			
NP		R. Mayrhofer <i>et al.</i> , 1980, "Simple-Preparation of 3-Benzylidene-2-azetidinones", <i>Synthesis</i> , 247-248			
NQ		Burrier, R.E. <i>et al.</i> , 1994, "Demonstration of a Direct Effect on Hepatic Acyl CoA:Cholesterol Acyl Transferase (ACAT) Activity By An Orally Administered Enzyme Inhibitor in the Hamster", <i>Biochemical Pharmacology</i> 47:1545-1551			
NR		Burrier, R.E. <i>et al.</i> , 1994, "The Effect of Acyl CoA:Cholesterol Acyltransferase Inhibitor on the Uptake, Esterification and Secretion of Cholesterol by the Hamster Small Intestine", <i>The Journal of Pharmacology and Experimental Therapeutics</i> 272:156-163			
NS		E.F. Binder <i>et al.</i> , "Effects of Hormone Replacement Therapy on Serum Lipids in Elderly Women. A Randomized, Placebo-Controlled Trial", <i>134 Ann. Intern. Med.</i> 9:754-760 (May 1, 2001)			
NT		MR Haymart <i>et al.</i> , "Optimal Management of Dyslipidemia in Women and Men", <i>2 J. Gen. Specif. Med.</i> 6:37-42 (Nov. - Dec. 1997)			
NU		"Framingham Heart Study Analysis Reveals Some Primary Prevention Subgroups Are Being Overlooked", <i>Heartwire</i> (April 12, 2001)			
NV		"Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)", "Third Report of the National Cholesterol Education Program (NCEP)", <i>NIH Publication No. 01-3670</i> (May 2001)			
NW		Van Heek <i>et al.</i> , "Ezetimibe, A Potent Cholesterol Absorption Inhibitor, Normalizes Combined Dyslipidemia in Obese Hyperinsulinemic Hamsters", <i>50 Diabetes</i> 1330-1335 (June 2001)			
NX		"Additional Statins Show Anti-Inflammatory Effect", <i>103 Circulation</i> 1933-35 (April 17, 2001)			
NY		H. Hauser, <i>et al.</i> , "Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine", <i>Biochemistry</i> 37:17843-17850, 1998			
NZ		G. Salen, <i>et al.</i> , "Sitosterolemia", <i>Journal of Lipid Research</i> 33:945-955, 1992			
OA	MD	Stedman's Medical Dictionary, 27 th Edition, pg. 1381			

APR 14 2003

Sheet 9 of 9

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K	SERIAL NO.: 10/057,629
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis	
				FILING DATE: January 25, 2002	
MS	OB	P.F. Belamarich <i>et al.</i> , "Response to Diet and Cholestyramine in a Patient with Sitosterolemia", <i>Pediatrics</i> , 977-981, (December 1990)			
	OC	G. Salen <i>et al.</i> , "Lethal Atherosclerosis Associated With Abnormal Plasma and Tissue Sterol Composition in Sitosterolemia With Xanthomatosis", <i>Journal of Lipid Research</i> , 1126-1133, (September 1985)			
	OD	G.R. Thompson <i>et al.</i> , "Novel Lipid-Regulating Drugs, Exp. Opin. Invest. Drugs, 9(11):2619-2628, 2000			
MS	OE	International Search Report dated December 18, 2002 corresponding to PCT Application No. PCT/US02/01195			
				DATE CONSIDERED	
				10/18/02	

32205

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

Sheet 1 of 1

PRIORITY TO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*

APPLICANT:

Harry R. Davis

FILING DATE:

January 25, 2002

GROUP:

1614**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

NA	AA	Exhibit A: SCH 58235 Micronized (ezetimibe), Drug Formulation Development Summary
	AB	Exhibit B: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AC	Exhibit C: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AD	Exhibit D: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AE	Exhibit E: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AF	Exhibit F: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AG	Exhibit G: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AH	Exhibit H: SCH 58235 (ezetimibe), Drug Formulation Development Summary
	AI	Exhibit 1: Master Sheet for the SCH 58235 and Lovastatin Research Study, <i>Schering-Plough Research Institute</i> (Protocol No. C906-411), page 1576-1585
	AJ	Exhibit 2: Medical Research Study #1055/97, SCH 58235: Bioavailability of Single Oral Doses of Two Prototype Tablet Formulations and the Reference Capsule Formulation of SCH 58235 in Normal Male Volunteers: A Four Way Crossover Study #C97-221-01, Informed Consent, <i>Peninsular Testing Corporation</i> , page 106-112
	AK	Exhibit 3: Consent Form to Participate in a Research Study, "A Phase II Double Blind Dose Response Investigation of Efficacy and Safety of Four Doses of SCH 58235 Compared to Placebo in Subjects with Primary Hypercholesterolemia," <i>Schering-Plough Research Institute</i> (Protocol No. C98-010), page 1558-1566
	AL	Exhibit 4: Medical Research Study #1096/99, SCH 58235: Pharmacokinetic Pharmacodynamic Drug Interaction Study with Digoxin in Healthy Volunteers #C98-114, Informed Consent, <i>Peninsular Testing Corporation</i> , page 124-130
NA	AM	Exhibit 5: Informed Consent, "SCH 58235: Assessment of Multiple-Dose Drug Interaction Between 58235 and Gemfibrozil in Healthy Volunteers," <i>Schering-Plough Research Institute</i> , page 1-8
EXAMINER		DATE CONSIDERED 10/16/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

TO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: CV01382K		SERIAL NO.: 10/057,629	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Harry R. Davis			
				FILING DATE: 01/25/2002		GROUP: 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>MS</i>	AL	WO 95/35277	12/28/95	PCT	C07D	205/08	
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>MS</i>	AQ	Thompson, G.R. <i>et al.</i> , "Novel lipid-regulating drugs" <i>Expert Opinion on Investigational Drugs</i> 9(11):2619-2628 (2000), XP008011782 abstract; figure 8					
<i>MS</i>	AR	Kosoglou, T. <i>et al.</i> , "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" <i>Atherosclerosis</i> 2:89 (2001), XP1132089 abstract					
	AS						
	AT						
	AU						
	AV						
EXAMINER <i>Myt</i>				DATE CONSIDERED 10/16/03			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



JUN 11 2003

TECH CENTER 1600/2900
Sheet 1 of 1

PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
CV01382KSERIAL NO.:
10/057,629INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT:
Harry R. Davis

(Use several sheets if necessary)

FILING DATE:
January 25, 2002GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

12	AQ	Luis Gruberg, MD, Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia, American Heart Association Scientific Sessions 2000				
	AR					
	AS					
	AT					
	AU					
	AV					

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.